Allergan CEO opposes fundamental shift in strategy, shares fall
Botox maker Allergan’s shares fell 4.2 percent to $155.16 (112.8 pounds) in late-morning trading, and are down more than a third over the last year. Allergan has hired multiple advisers, Saunders said on a Monday conference call following the company’s quarterly earnings. It is considering five options: deploying capital to buy back shares, doing divestitures, splitting the company, making acquisitions, or continuing to operate Allergan as is. …read more […]